Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Avalo Therapeutics Inc (AVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/24/2026: AVTX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.11
1 Year Target Price $36.11
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 273.99M USD | Price to earnings Ratio - | 1Y Target Price 36.11 |
Price to earnings Ratio - | 1Y Target Price 36.11 | ||
Volume (30-day avg) 8 | Beta 0.89 | 52 Weeks Range 3.39 - 20.72 | Updated Date 02/24/2026 |
52 Weeks Range 3.39 - 20.72 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -34632.29% |
Management Effectiveness
Return on Assets (TTM) -37.18% | Return on Equity (TTM) -174.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58397628 | Price to Sales(TTM) 1427.03 |
Enterprise Value 58397628 | Price to Sales(TTM) 1427.03 | ||
Enterprise Value to Revenue 132.42 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 18512757 | Shares Floating 11772391 |
Shares Outstanding 18512757 | Shares Floating 11772391 | ||
Percent Insiders 3.48 | Percent Institutions 111.84 |
Upturn AI SWOT
Avalo Therapeutics Inc
Company Overview
History and Background
Avalo Therapeutics Inc. (formerly iBio, Inc.) was established in 2002. The company has undergone significant transformations, including a name change from iBio, Inc. to Avalo Therapeutics Inc. in early 2023. This rebranding reflects a strategic shift towards a more focused pipeline in immunology and oncology, leveraging its proprietary platform technologies. Historically, the company was known for its development of plant-made biopharmaceuticals and its FAST (Functional Affinity Screening Technology) platform.
Core Business Areas
- Immunology and Oncology Pipeline: Avalo Therapeutics is focused on developing novel therapeutics for immuno-oncology and autoimmune diseases. Their pipeline includes drug candidates targeting various stages of disease, aiming to leverage its understanding of immune system modulation.
- Proprietary Technology Platforms: The company utilizes advanced technology platforms, including FAST (Functional Affinity Screening Technology), to accelerate drug discovery and development. These platforms aim to identify and optimize therapeutic candidates with high specificity and efficacy.
Leadership and Structure
Avalo Therapeutics Inc. is led by a management team with expertise in biotechnology and pharmaceutical development. The organizational structure is designed to support research and development, clinical trials, and strategic partnerships. Key leadership roles typically include Chief Executive Officer, Chief Medical Officer, and Chief Financial Officer.
Top Products and Market Share
Key Offerings
- Product Name 1: AVLO-001 (formerly IBIO-201): A monoclonal antibody candidate targeting CD28 to enhance T-cell responses in cancer. Competitors include companies developing checkpoint inhibitors and other T-cell stimulating agents in the immuno-oncology space. Market share data is not yet applicable as it is in early development.
- Product Name 2: AVLO-002 (formerly IBIO-202): A therapeutic candidate aimed at modulating immune responses for autoimmune diseases. Competitors include existing biologics and small molecules used in the treatment of various autoimmune conditions. Market share data is not yet applicable as it is in early development.
Market Dynamics
Industry Overview
The biotechnology industry, particularly in the areas of immuno-oncology and autoimmune diseases, is characterized by rapid innovation, significant investment, and intense competition. There is a strong demand for novel therapies that offer improved efficacy, safety, and patient outcomes. The market is driven by advancements in scientific understanding of disease mechanisms and sophisticated drug discovery technologies.
Positioning
Avalo Therapeutics Inc. is positioning itself as an innovator in the immuno-oncology and autoimmune disease space, aiming to address unmet medical needs. Its strength lies in its proprietary technology platforms that enable efficient drug discovery and development. The company seeks to leverage these platforms to build a robust pipeline of differentiated therapeutic candidates.
Total Addressable Market (TAM)
The TAM for immuno-oncology and autoimmune disease therapeutics is substantial and growing, with billions of dollars in annual sales globally. Avalo Therapeutics Inc. is positioned to capture a portion of this market by developing novel therapies that offer significant advantages over existing treatments. Their focus on specific immunological targets allows them to carve out niches within these broad therapeutic areas.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (e.g., FAST) for accelerated drug discovery.
- Focused pipeline in high-growth areas of immuno-oncology and autoimmune diseases.
- Experienced leadership team with biotech expertise.
- Potential for differentiated therapeutic candidates.
Weaknesses
- Early-stage pipeline with significant development and regulatory hurdles.
- Limited commercial track record as a rebranded entity.
- Dependence on external funding for continued research and development.
- Need to establish strong clinical trial data to validate pipeline candidates.
Opportunities
- Significant unmet needs in target therapeutic areas.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in scientific understanding of immunology and oncology.
- Expanding market for novel cancer and autoimmune therapies.
Threats
- Intense competition from established pharmaceutical companies and other biotech firms.
- High failure rates in drug development.
- Stringent regulatory requirements and lengthy approval processes.
- Economic downturns impacting investment in the biotech sector.
- Patent expirations and the rise of generics for existing treatments.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co., Inc. (MRK)
- Roche Holding AG (RHHBY)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
Competitive Landscape
Avalo Therapeutics Inc. operates in highly competitive markets with many established players. Its competitive advantage lies in its specialized focus on specific targets within immuno-oncology and autoimmune diseases, and its proprietary technology platforms that may allow for more efficient discovery and development. However, it faces challenges in competing with the vast resources, established sales forces, and extensive pipelines of larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historically, under its previous name (iBio, Inc.), the company focused on various therapeutic areas and platform technologies. The rebranding to Avalo Therapeutics Inc. signifies a strategic pivot, and its growth trajectory is now tied to the advancement of its current immuno-oncology and autoimmune pipeline.
Future Projections: Future growth projections are highly contingent on the successful progression of its lead drug candidates through clinical trials, regulatory approvals, and eventual commercialization. Analyst estimates, if available, would typically focus on potential peak sales of pipeline assets.
Recent Initiatives: Key recent initiatives include the rebranding to Avalo Therapeutics Inc., strategic shifts in its pipeline focus, and ongoing efforts to advance its lead drug candidates through preclinical and clinical development phases. The company may also be pursuing strategic partnerships or collaborations to fund and accelerate development.
Summary
Avalo Therapeutics Inc. is a biotechnology company undergoing a strategic transformation with a focus on immuno-oncology and autoimmune diseases. Its strengths lie in its proprietary technology platforms and focused pipeline, while its weaknesses include its early-stage development and reliance on external funding. The company has significant opportunities in addressing unmet medical needs but faces substantial threats from intense competition and the high risks associated with drug development. Careful execution of its development strategy and successful clinical outcomes will be critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (e.g., SEC filings)
- Biotechnology Industry Analysis Reports
- Financial News and Data Providers (e.g., Bloomberg, Reuters, Yahoo Finance)
- Company Website
Disclaimers:
This information is provided for informational purposes only and does not constitute financial advice. Stock market investments are subject to risks, and investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is an estimation and may not be precise. Specific financial data and competitive landscapes can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.avalotx.com |
Full time employees 23 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.